1 / 1

Antisense Oligonucleotides Market

Antisense oligonucleotides (ASOs) are single-stranded DNA molecules that are changed to restrict the expression of their mRNA targets in order to regulate inappropriate gene expression in pathological circumstances.

poojabasmunge
Télécharger la présentation

Antisense Oligonucleotides Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Antisense Oligonucleotides Market Global Industry Analysis, Size, Share and Forecast Antisense oligonucleotides (ASOs) are single-stranded DNA molecules that are changed to restrict the expression of their mRNA targets in order to regulate inappropriate gene expression in pathological circumstances. Spinal muscular atrophy, Duchenne muscular dystrophy, and other hereditary illnesses are treated with ASOs. Market Dynamics The market for antisense oligonucleotides is predicted to rise due to the high prevalence of cancer. According to the American Cancer Society, there will be 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States year 2019. Expanding interest in R&D of cancer is relied upon to offer worthwhile development openings for major parts in antisense oligonucleotides market. For example, as indicated by the National Cancer Research Institute (NCRI), cancer research financing by NCRI accomplices stretched around US$ 750 million out of 2018/19. In addition, high pervasiveness of genetic disorders is likewise expected to help in development of the market. For example, as indicated by the investigation, 'Transporter recurrence of SMN1-related spinal solid decay in north Indian populace: The requirement for populace based screening program' distributed in American Journal of Medical Genetics in October 2020, the transporter recurrence of Spinal Muscular Atrophy (SMN)1 cancellation was 1 of every 38 (16 out of 606). Read More: https://bit.ly/3hzd2nB Coherent Market Insights

More Related